Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 18Completed 14Terminated 6Withdrawn 4Unknown 4Active not recruiting 3Not yet recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

NET 71Endocrine 71Gastrointestinal 8CNS 4Thoracic 3Sarcoma 2Lymphoid 2Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Brain Neoplasms 264Glioblastoma 193Glioma 159Neuroblastoma 56Central Nervous System Neoplasms 55Astrocytoma 45Carcinoma, Non-Small-Cell Lung 39Neoplasms 32Breast Neoplasms 27Oligodendroglioma 26Meningioma 23Recurrence 21Neuroma, Acoustic 21Neoplasm Metastasis 20Meningeal Carcinomatosis 20Gliosarcoma 20Neurofibromatosis 1 18Medulloblastoma 18Lung Neoplasms 15Paraganglioma 14Lymphoma 14Pheochromocytoma 13Spinal Cord Neoplasms 12Sarcoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Burkitt Lymphoma 9Pancreatic Neoplasms 8Ovarian Neoplasms 7Melanoma 7Esophageal Neoplasms 7

Interventions

lutetium Lu 177 dotatate 190Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Neuroendocrine Tumors × CNS × Clear all
NCT04017104 2021-01-26

Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging

British Columbia Cancer Agency

Unknown
60 enrolled
CNSEndocrineGenitourinaryNET

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Prostatic Neoplasms, Neuroendocrine Tumors

NCT03734913 2020-07-22

A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors

Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Phase 1 Unknown
65 enrolled
CNSDermatologicEndocrineNETThoracic

Carcinoma, Basal Cell, Glioblastoma, Medulloblastoma, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04029428 2020-04-01

POLNETS_PRRT

University of Warmia and Mazury

Phase 2 Unknown
150 enrolled
CNSEndocrineNET

Paraganglioma, Neuroendocrine Tumors

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡